Mutations in the genes encoding the cytoplasmic and mitochondrial forms of isocitrate
dehydrogenase (IDH1 and IDH2, respectively; collectively referred to as IDH) are frequently …

The identification of heterozygous neomorphic isocitrate dehydrogenase (IDH) mutations
across multiple cancer types including both solid and hematologic malignancies has …

Hotspot mutations in isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2
(IDH2) occur in a variety of myeloid malignancies and solid tumors. Mutant IDH proteins …

Gliomas are the most common malignant primary brain tumours in adults and cannot usually
be cured with standard cancer treatments. Gliomas show intratumoural and intertumoural …

Epigenetic lesions that disrupt regulatory elements represent potential cancer drivers.
However, we lack experimental models for validating their tumorigenic impact. Here, we …

Establishing causal links between inherited polymorphisms and cancer risk is challenging.
Here, we focus on the single-nucleotide polymorphism rs55705857, which confers a sixfold …

The identification of recurrent point mutations in the isocitrate dehydrogenase 1 (IDH1)
gene, albeit in only a small percentage of glioblastomas a decade ago, has transformed our …

Although hotspot mutations in isocitrate dehydrogenase (IDH) genes are associated with
favorable clinical outcomes in glioma, CDKN2A/B homozygous deletion has been identified …

Low-grade astrocytomas (LGAs) carry neomorphic mutations in isocitrate dehydrogenase
(IDH) concurrently with P53 and ATRX loss. To model LGA formation, we introduced R132H …

Gliomas are primary brain tumours that are thought to develop from neural stem or
progenitor cells that carry tumour-initiating genetic alterations. Based on microscopic …